Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD

Related Keywords

Canada ,New York ,United States ,Toronto ,Ontario ,Jake Edmiston ,Edwarda Fox ,Kevin Carmichael ,Gabriel Friedman ,John Stone ,Zenas Biopharma ,Postmedia Network Inc ,Xencor Inc ,Twitter ,National Post ,Linkedin ,Professor Of Medicine At Harvard Medical School ,Zenas Biopharma Announces Publication ,Investigational Treatment ,Related Disease ,Lancet Rheumatology ,Victoria Wells ,Financial Times ,Financial Post ,New York Times ,Postmedia Network ,Street East ,Pilot Study ,Evaluate Efficacy ,Harvard Medical School ,Mass General ,Media Contact ,